Full-Time

Domain Architect

Diagnostics R&D

Updated on 7/22/2026

Roche

Roche

1-10 employees

Global pharmaceuticals and diagnostics company

Compensation Overview

PLN280k - PLN520k/yr

Indianapolis, IN, USA

In Person

Category
Architecture & Civil Engineering (1)
Required Skills
Infrastructure as Code (IaC)
Microservices
AWS
Observability

Get referred to Roche

Find people who can refer or advise you

Requirements
  • Bachelor’s or Master’s degree with 7+ years of experience in IT and architecture
  • Deep domain experience within the Diagnostics R&D environment. Comprehensive understanding of the scientific, clinical, and engineering processes (e.g., Computational Science, Instrumentation, Laboratory Operations) that drive diagnostics innovation forward.
  • A successful history of contributing as a Domain or Enterprise Architect within a complex, matrixed, or federated global organization.
  • Proficiency in designing target-state architectures and evolving capability roadmaps for complex R&D organizations.
  • Cloud-native architecture on AWS: microservices, event-driven patterns, API-first design, infrastructure-as-code. Practical experience with multi-tenant scientific platforms, not just enterprise SaaS.
  • Data architecture for R&D: lakehouse patterns, streaming and batch pipelines, data lineage, and observability across heterogeneous scientific data sources.
  • Regulatory-aware architecture in Diagnostics or Life Sciences (IEC 62304, 21 CFR Part 11, EU IVDR, GxP) — able to meet compliance requirements without defaulting to heavyweight processes.
  • Application portfolio rationalization: dependency mapping, decommissioning sequencing, data migration, and the governance to sunset legacy systems without breaking business continuity.
  • Cross-domain technical fluency spanning clinical development systems, computational science platforms, laboratory informatics (LIMS, ELN), and instrumentation. Must be able to challenge and align Solution Architects across these domains.
  • Knowledge of architecture frameworks (e.g., TOGAF) as a reference.
  • Experience utilizing flexible delivery methodologies to drive meaningful value, prioritizing practical outcomes over rigid process adherence. We value tradeoff analysis.
  • A thorough and pragmatic approach to developing sustainable, outcome-driven solutions.
Responsibilities
  • Strategic Business Partnering: Act as the strategic liaison between SPG EA and Diagnostics R&D. Partner with the Head of Dia RDT for DIA R&D and the R&D DT Leadership team to align business priorities with multi-year roadmaps and target-state architectures and ensure domain strategies are coherent with enterprise strategies.
  • Architecture Network Orchestration: Lead the Diagnostics R&D architecture network by shaping and promoting shared strategic priorities. Enable Domain and Solution Architects to execute efficiently while maintaining alignment and maximizing the use of shared principles and platforms.
  • Architecture Governance Leadership: Provide leadership for governance activities across Diagnostics R&D in collaboration with other embedded domain architects. Oversee architecture deliverables, technology guardrails, and create alignment on non-functional requirements (e.g., security, resilience). Represent architecture within other Governance bodies (e.g. Portfolio).
  • Critical Program Delivery: Drive the success of large, critical technology programs in Diagnostics R&D. Translate strategy into action and ensure transformative initiatives deliver intended business value while providing architectural oversight.
  • Domain Architecture Deliverables: Lead the development and upkeep of core architecture artifacts for Diagnostics R&D. Ensure data accuracy across the standard architecture and RDT toolchain, delivering key outputs such as Capability Maps, Target-State Architectures, Architecture Standards, and Reference Architectures.
  • Portfolio & Investment Alignment: Work with Diagnostics R&D Portfolio Management and Functional Heads to embed architectural insights into investment decisions. Evaluate the impacts of strategies, address architectural gaps, and prevent fragmentation by maximizing platform reuse and managing technical debt.
  • Technology Innovation & Vendor Evaluation: Monitor emerging technology trends and evaluate vendors to ensure alignment with Diagnostics R&D needs. Stay updated on vendor developments to maintain an effective and future-ready architecture.
Desired Qualifications
  • AI/ML platform architecture: model serving, GPU orchestration, ML pipelines at organizational scale.
  • Agentic AI patterns: tool orchestration, agent-to-agent protocols (MCP, A2A), guardrails, and human-in-the-loop design for scientific workflows. Usage of LLMs and SLM in Lifesciences.
  • Instrumentation and lab systems integration: edge-to-cloud telemetry, instrument data acquisition, OT/IT boundary in diagnostics.
  • Proven ability to govern through influence, reference architectures, and design reviews rather than gate-based control.
  • Understanding of Hardware Development patterns.
  • Network & Community Leadership: Demonstrated ability in leading and influencing federated networks of architects without direct reporting lines.
  • Strategic Advisory & Executive Influence: Builds trust and serves as a trusted advisor to senior leadership and Global Function Heads. Combines business acumen and executive presence to guide strategic decisions and influence senior stakeholders without direct authority.
  • Effective Communication: Excels in storytelling, translating complex architectural concepts into relatable narratives. Balances enterprise coherence with the agility and autonomy of local Diagnostics R&D execution.

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Roche targets top-three obesity status by 2030 via CT-388 and petrelintide assets.
  • The $1.5B Poseida acquisition secures off-the-shelf CAR-T therapies for oncology and immunology.
  • AI-driven diagnostics gain traction through the $750M PathAI acquisition closing in 2026 H2.

What critics are saying

  • Kadcyla and Perjeta biosimilar erosion in 2025–2026 will strip billions from oncology revenue.
  • Ocrevus loss of exclusivity in 2029 threatens the entire immunology franchise profitability.
  • Eight cancer drugs face biosimilars by 2030, risking CHF 6.7B sales decline easily.

What makes Roche unique

  • Roche uniquely integrates Pharmaceuticals and Diagnostics under one roof for personalized healthcare.
  • Only Roche combines world-class drug R&D with global diagnostics leadership seamlessly.
  • Roche leverages companion diagnostics to pair targeted therapies with precise patient identification.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company News

Dealroom.co
Apr 16th, 2026
SAGA company information, funding & investors

SAGA, providing cancer companion diagnostic testing of tissue and non-invasive monitoring of circulating tumor dna (ctdna). Here you'll find information about their funding, investors and team.

Yahoo Finance
Apr 13th, 2026
Roche receives CE mark for Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis

Roche has received CE mark approval for its Elecsys Neurofilament Light Chain blood test to detect neuroinflammation in adults with relapsing remitting multiple sclerosis. The test measures NfL, a protein released during nerve cell injury, providing insight into neuroaxonal damage associated with the disease. Multiple sclerosis affects over 2.9 million people worldwide. Whilst early and regular monitoring is critical, patients often struggle to access routine MRI scans. The minimally invasive blood test offers a more accessible alternative, complementing clinical assessments and potentially enabling earlier intervention. The test runs on Roche's widely available cobas instruments, delivering standardised results and requiring only a simple blood sample. This reduces the need for patients to travel to specialist centres, making frequent monitoring more practical where traditional testing faces geographic, financial or logistical barriers.

Bizwatch
Apr 12th, 2026
Roche invests $20M in degrader-antibody conjugate platform via C4 Therapeutics deal worth up to $1B

Roche has partnered with C4 Therapeutics to develop degrader-antibody conjugates (DACs), marking a $20 million upfront payment with potential milestone payments exceeding $1 billion. The collaboration targets cancer therapeutics using C4's Torpedo platform. DACs represent a next-generation approach to antibody-drug conjugates (ADCs). Whilst ADCs attach cytotoxic drugs to antibodies, DACs use targeted protein degradation payloads to selectively eliminate specific proteins within cancer cells, potentially reducing toxicity and drug resistance whilst accessing previously difficult targets. Amongst Korean listed companies, Orum Therapeutics leads DAC development, having licensed ORM-6151 to Bristol Myers Squibb in 2023. Y-Biologics partnered with Ubix Therapeutics, whilst Oscotec is developing three DAC pipelines through subsidiary Genosco, targeting technology transfers after 2028.

Yahoo Finance
Mar 30th, 2026
Roche gets FDA clearance for cobas c703 and ISE neo lab testing units with 2,000 tests per hour

Roche has received FDA 510(k) clearance for its cobas c703 and cobas ISE neo analytical units, designed to enhance laboratory efficiency through increased automation and testing capacity. The units are part of Roche's cobas pro integrated solutions platform. The cobas c703 delivers up to 2,000 tests per hour with 70 reagent positions, doubling clinical chemistry throughput whilst reducing reagent reloads. The cobas ISE neo provides up to 1,800 tests per hour with automated maintenance, reducing hands-on time and plastic waste compared to previous systems. Both units feature monthly operator maintenance to improve uptime and help laboratories address staffing shortages and growing test volumes. Roche has over 4,000 cobas analysers installed across the United States.

Yahoo Finance
Mar 30th, 2026
Roche launches cobas MPX-E assay, 4-in-1 donor screening test for HIV, HCV, HBV and HEV

Roche has launched the cobas MPX-E assay, a four-in-one donor screening test that simultaneously detects HIV, Hepatitis C, B and E viruses. The test is now available in countries accepting the CE mark. The assay consolidates detection of four major viral targets into a single workflow, improving laboratory efficiency and reducing costs. It features dual-target detection for HIV-1 and enhanced sensitivity for Hepatitis E, which causes an estimated 20 million infections and 70,000 deaths annually worldwide. The test runs on Roche's fully automated cobas x800 systems, which process over 10 million tests monthly across laboratories globally. The ready-to-load reagents enable up to eight hours of walk-away time. The nucleic acid testing blood screening market is valued at approximately 800 million Swiss francs globally, with an expected annual growth rate of 2% through 2029.